Brain Behavior and Immunity, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Brain Behavior and Immunity, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Parkinsonism & Related Disorders, Год журнала: 2025, Номер unknown, С. 107314 - 107314
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0Neuroglia, Год журнала: 2025, Номер 6(2), С. 17 - 17
Опубликована: Апрель 4, 2025
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms, with increasing evidence supporting the role of immune dysregulation in its pathophysiology. Neuroinflammation, mediated microglial activation, pro-inflammatory cytokine production, blood–brain barrier dysfunction, plays crucial dopaminergic neuronal degeneration. Furthermore, peripheral changes, including T cell infiltration, gut microbiota dysbiosis, systemic inflammation, contribute to progression. The bidirectional interaction between central systems suggests that immune-based interventions may hold therapeutic potential. While treatments remain standard care, immunomodulatory therapies, monoclonal antibodies targeting α-synuclein, deep brain stimulation (DBS) have demonstrated immunological effects, though clinical efficacy remains uncertain. Advances phenotyping offer new avenues for personalized treatment approaches, optimizing responses stratifying patients based on inflammatory biomarkers. This review highlights complexities involvement PD discusses emerging strategies pathways develop disease-modifying treatments.
Язык: Английский
Процитировано
0Brain Behavior and Immunity, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Язык: Английский
Процитировано
0